DOCSLIB.ORG

Patent No.: US 9187749 B2 EXPRESSION 29-33 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patent No.: US 9187749 B2 EXPRESSION 29-33 3 US009 187749B2 (12) United States Patent (10) Patent No.: US 9,187,749 B2 Bhattacharjee et al. (45) Date of Patent: Nov. 17, 2015 (54) METHODS FOR MODULATING FACTOR 12 6,794,499 B2 9/2004 Wengel et al. EXPRESSION 29-33 3: Wengeet al. W - - enge 7,399,845 B2 7/2008 Seth et al. (75) Inventors: Gourab Bhattacharjee, San Diego, CA 7.427.672 B2 9/2008 Imanishi et al. (US); Alexey Revenko, San Diego, CA 7,547,684 B2 6/2009 Seth et al. (US); Robert A. MacLeod, San Diego, 7,696,345 B2 4/2010 Allerson et al. CA (US) 2001/005.3519 A1 12/2001 Fodor et al. 2003/0228597 A1 12/2003 COWSert et al. 2004/0171570 A1 9, 2004 A11 tal. (73) Assignee: s rhymaceutical, Inc., Carlsbad, 2005/O130923 A1 6, 2005 SN al 2007/0031844 A1 2/2007 Khvorova et al. 2007/0192882 A1* 8, 2007 Dewald ........................... 800, 14 (*) Notice: Subject to any disclaimer, the term of this 2008/0039618 A1 2/2008 Allerson et al. patent is extended or adjusted under 35 3.93.9 A. 1939. Ny's al. U.S.C. 154(b) by 38 days. 2009 OO64350 A1 3, 2009 Dewaldwayze et al. 2010.01374.14 A1 6, 2010 Freier et al. (21) Appl. No.: 14/124,621 2010/03241 14 A1 12/2010 Dewald 2011/0067.124 A1 3/2011 Dewald ........................... 800, 13 (22) PCT Filed: Jun. 8, 2012 2012/0309035 A1 12/2012 Lindahl et al. .................. 435/13 2013/0331434 A1* 12/2013 Monia et al. ................ 514.f44 A (86). PCT No.: PCT/US2012/041747 S371 (c)(1) FOREIGN PATENT DOCUMENTS C s (2), (4) Date: Feb. 28, 2014 WO WO99,14226 3, 1999 WO WOO3,OO46O2 1, 2003 (87) PCT Pub. No.: WO2012/170947 W. W. 39.95. 1339. PCT Pub. Date: Dec. 13, 2012 WO WO 2007 134181 11, 2007 WO WO 2008.101157 8, 2008 (65) Prior Publication Data WO WO 2008,150729 12/2008 WO WO 2008,1544O1 12/2008 US 2014/02283OO A1 Aug. 14, 2014 WO WO 2009 OO6478 1, 2009 WO WO 2009/115478 9, 2009 WO WO 2010/094732 8, 2010 Related U.S. Application Data (Continued) (60) Provisional application No. 61/495,943, filed on Jun. 10, 2011, provisional application No. 61/496,456, OTHER PUBLICATIONS filed on Jun. 13, 2011. DonaldOa. Kylee C tPh aaCCCatical DesignS. 1995 1233-254.* (51) Int. Cl. Merriam-Webster online retrieved on Mar. 5, 2015 definition for CI2N IS/II (2006.01) prophylactically. Retrieved from: Google, pp. 1-3.* CI2N IS/II3 (2010.01) Cugno et al. Trends Mol. Med. 15:69-78, 2009.* A6 IK 4.8/00 (2006.01) Adcock et al., “A laboratory approach to the evaluation of hereditary A6 IK3I/7088 (2006.01) hypercoagulability” Am. J. Clin. Pathol. (1997) 108(4):434-449. A6 IK 45/06 (2006.01) (Continued) (52) U.S. Cl. CPC ........ CI2N 15/1137 (2013.01); A61 K3I/7088 (2013.01); A61K 45/06 (2013.01); A61 K Primary Examiner — Brian Whiteman 48/005 (2013.01); C12N 15/113 (2013.01); CI2N 2310/11 (2013.01); C12N 23.10/315 . 4) tigny Agent, or Firm — Knobbe, Martens, Olson & (2013.01); C12N 23.10/3231 (2013.01); C12N Ca 23.10/3341 (2013.01); C12N 23.10/341 O A O (2013.01) (57) ABSTRACT (58) Field of Classification Search CPC ........... C12N 2310/11; C12N 23.10/31; C12N Disclosed herein are methods for decreasing Factor 12 and 2310/32: C12N 231 O/33 treating or preventing inflammatory conditions in an indi See application file for complete search history. vidual in need thereof. Examples of disease conditions that (56) References Cited can be ameliorated with the administration of antisense com pounds targeted to Factor 12 include hereditary angioedema U.S. PATENT DOCUMENTS (HAE). Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for 5,801,154 A 9, 1998 Baracchini et al. developing an inflammatory condition, such as, hereditary 6,268,490 B1 7/2001 Imanishi et al. 6,525, 191 B1 2/2003 Ramasamy angioedema. 6,582,908 B2 6, 2003 Fodor et al. 6,670,461 B1 12/2003 Wengel et al. 6,770,748 B2 8/2004 Imanishi et al. 22 Claims, 2 Drawing Sheets US 9,187,749 B2 Page 2 (56) References Cited Foster et al., “Inhibition of the activation of Hageman factor (factor XII) by extracts of Schistosoma mansoni.” J. Lab. Clin. Med. (1992) 120(5): 735-9. FOREIGN PATENT DOCUMENTS Freier et al., “The ups and downs of nucleic acid duplex stability: WO WO 2010/11 1702 9, 2010 structure-stability studies on chemically-modified DNA:RNA WO WO 2012/0647.58 5, 2012 duplexes” Nucleic Acids Research (1997) 25(22):4429-4443. WO WO 2012/170947 12/2012 Frieden et al., “Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA'Nucleic Acids Research (2003) OTHER PUBLICATIONS 31(21):6365-6372. Gautschi et al., “Activity of a Novel bcl-2/bcl-XL-Bispecific Albaek et al., “Analogues of a Locked Nucleic Acid with Three Antisense Oligonucleotide Against Tumors of Diverse Histologic Carbon 2',4'-Linkages: Synthesis by Ring-Closing Metathesis and Origins' J. Natl. Cancer Inst. (2001) 93(6):463-471. Influence of Nucleic Acid Duplex Stability” J. Org. Chem. (2006) Gigliet al., “Interaction of plasmakallikrein with the C1 inhibitor.” J. 71:7731-774O. Immunol. (1970) 104:574-581. Altmann et al., “Second-generation antisense oligonucleoties: struc Han et al., “Increased vascular permeability in C1 inhibitor-deficient ture-activity relationships and the design of improved signal mice mediated by the bradykinin type 2 receptor.” J. Clin. Invest. transduction inhibitors' Biochem. Soc. Trans. (1996) 24: 630-637. (2002) 109: 1057-1063. Altmann et al., “Second Generation of Antisense Oligonucleotides: Hazegh-Azam et al., “The Corn Inhibitor of Activated Hageman From Nuclease Resistance to Biological Efficacy in Animals” Factor: Purification and Properties of Two Recombinant Forms of the Chimia (1996) 50: 168-176. Protein’ Protein Expr. Purif. (1998) 13(2): 143-149. Altmann et al., “Second Generation AntiSense Oligonucleotides— Hojima et al., “Pumpkin seed inhibitor of human factor XIIa (acti Inhibition of PKC-a and c-RAF Kinase Expression by Chimeric vated Hageman factor) and bovine trypsin' Biochemistry (1982) Oligonucleotides Incorporating 5'-Substituted Carbocyclic 21(16): 3741-3746. Nucleosides and 2'-O-Ethylene Glycol Substituted Ribonucleosides' Isawa et al., “Identification and characterization of plasmakallikrein Nucleosides Nucleotides (1997) 16(7-9): 917-926. kinin System inhibitors from Salivary glands of the blood-sucking Altschul et al., “Basic Local Alignment Search Tool” J. Mol. Biol. insect Triatoma infestans.” FEBS J. (2007) 274(16): 4271-4286. (1990) 215: 403-410. Kaplanet al., “Pathways for bradykinin formation and inflammatory Aulak et al., "Chymotrypsin inhibitory activity of normal C1-inhibi disease.” J. Allergy Clin. Immunol. (2002) 109(2): 195-209. tor and a P1 Arg to His mutant: evidence for the presence of overlap Kato et al., “Identification and characterization of the plasma kal ping reactive centers.” Protein Sci. (1993)2(5): 727-732. likrein-kinin system inhibitor, haemaphysalin, from hard tick, Bertina et al., “Mutation in blood coagulation factor V associated Haemaphysalis longicornis' Thromb. Haemost. (2005) 93: 359-67. with resistance to activated protein C.” Nature (1994)369(6475):64 Kleinschnitz et al., “Targeting coagulation factor XII provides pro 67. tection from pathological thrombosis in cerebral ischemia without Bjorket al., “Mechanism of the anticoagulantaction of heparin.” Mol interfering with hemostasis' J. Exper. Med. (2006) 203:513-518. Cell Biochem. (1982) 48(3):161-182. Koshkin et al., “LNA (Locked Nucleic Acids): Synthesis of the Bouillet et al. “Disease expression in women with hereditary Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil angioedema' Am. J. Obstet. Gynecol. (2008) 199: 484.e1-484.e4. Biocyclonucleoside Monomers, Oligomerisation, and Unprec Braasch et al., “Locked nucleic acid (LNA): fine-tuning the recogni edented Nucleic Acid Recognition’ Tetrahedron (1998). 54:3607 tion of DNA and RNA” Chem. Biol. (2001) 8:1-7. 3630. Branch et al., “A good antisense molecule is hard to find.” TIBS Kumar et al., “The First Analogues of LNA (Locked Nucleic Acids): (1998) 23:45-50. Phosphorothioate-LNA and 2'-Thio-LNA' Bioorg. Med. Chem. Lett. Chan et al., “The inhibition of activated factor XII (hageman factor) (1998) 8:2219-2222. by antithrombin III: The effect of other plasma proteinase inhibitors' Leumann, “DNA Analogues: From Supramolecular Principles to Biochem. Biophys. Res. Comm. (1977) 74(1): 150-158. Biological Properties' Bioorganic & Medicinal Chemistry (2002) Cichon et al., “Increased activity of coagulation factor XII (Hageman 10:841-854. factor) causes hereditary angioedema type III Am. J. Hum. Genet. Mackenzie et al., “Plasma prekallikrein levels are positively associ (2006) 79: 1098-1104. ated with circulating lipid levels and the metabolic syndrome in Citarella et al., “The Second Exon-Encoded Factor XII Region Is children.” Appl. Physiol. Nutr. Metab. (2010) 35: 518-525. Involved in the Interaction of Factor XII With Factor XI and DoesNot Mahdiet al., “Factor XII interacts with the multiprotein assembly of Contribute to the Binding Site for Negatively Charged Surfaces” urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 Blood (1998) 92: 41.98-4206. on endothelial cell membranes' Blood (2002)99(10): 3585-3596. Citarella et al., “Identification of aputative binding site for negatively Maher et al., “Comparative hybrid arrest by tandem antisense charged surfaces in the fibronectin type II domain of human factor oligodeoxyribonucleotides O oligodeoxyribonucleoside XII—an immunochemical and homology modeling approach.” methylphosphonates in a cell-free system” Nuc. Acid. Res. (1988) Thromb. Haemost. (2000) 84(6): 1057-1065. 16:3341-3358.
Load more

Recommended publications
  • A Guardian of the Development of Diabetic Retinopathy
    Diabetes Volume 67, April 2018 745 Sirt1: A Guardian of the Development of Diabetic Retinopathy Manish Mishra, Arul J. Duraisamy, and Renu A. Kowluru Diabetes 2018;67:745–754 | https://doi.org/10.2337/db17-0996 Diabetic retinopathy is a multifactorial disease, and the molecular mechanism of the development of diabetic reti- exact mechanism of its pathogenesis remains obscure. nopathy remains to be established. Sirtuin 1 (Sirt1), a multifunctional deacetylase, is impli- Sirtuin 1 (Sirt1), a member of the silent information cated in the regulation of many cellular functions and in regulator 2 family, is a class III histone deacetylase that gene transcription, and retinal Sirt1 is inhibited in di- interacts with target proteins and regulates many cellular abetes. Our aim was to determine the role of Sirt1 in the functions including cell proliferation, apoptosis, and inflam- development of diabetic retinopathy and to elucidate the matory responses (6–8). Sirt1 is mainly a nuclear protein, Sirt1 molecular mechanism of its downregulation. Using - and its activity depends on cellular NAD availability (9). It is overexpressing mice that were diabetic for 8 months, Sirt1 expressed throughout the retina, and upregulation of COMPLICATIONS structural, functional, and metabolic abnormalities were protects against various ocular diseases including retinal investigated in vascular and neuronal retina. The role of degeneration, cataract, and optic neuritis (10). Our previous epigenetics in Sirt1 transcriptional suppression was inves- work has shown that Sirt1 expression and activity are de- tigated in retinal microvessels. Compared with diabetic wild-type mice, retinal vasculature from diabetic Sirt1 mice creased in the retina and its capillary cells in diabetes (11).
    [Show full text]
  • Cytosine-Rich
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 12116-12121, October 1996 Chemistry Inter-strand C-H 0 hydrogen bonds stabilizing four-stranded intercalated molecules: Stereoelectronic effects of 04' in cytosine-rich DNA (base-ribose stacking/sugar pucker/x-ray crystallography) IMRE BERGERt, MARTIN EGLIt, AND ALEXANDER RICHt tDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and tDepartment of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611-3008 Contributed by Alexander Rich, August 19, 1996 ABSTRACT DNA fragments with stretches of cytosine matic cytosine ring systems from intercalated duplexes (Fig. 1A). residues can fold into four-stranded structures in which two Second, unusually close intermolecular contacts between sugar- parallel duplexes, held together by hemiprotonated phosphate backbones in the narrow grooves are observed, with cytosine-cytosine+ (C C+) base pairs, intercalate into each inter-strand phosphorus-phosphorus distances as close as 5.9 A other with opposite polarity. The structural details of this (5), presumably resulting in unfavorable electrostatic repulsion if intercalated DNA quadruplex have been assessed by solution not shielded by cations or bridging water molecules. NMR and single crystal x-ray diffraction studies of cytosine- The close contacts between pairs of antiparallel sugar- rich sequences, including those present in metazoan telo- phosphate backbones from the two interdigitated duplexes are meres. A conserved feature of these structures is the absence a unique characteristic of four-stranded intercalated DNA. of stabilizing stacking interactions between the aromatic ring Indeed, the unusually strong nuclear overhauser effect signals systems of adjacent C-C+ base pairs from intercalated du- between inter-strand sugar Hi' protons and Hi' and H4' plexes.
    [Show full text]
  • REDUCTION of PURINE CONTENT in COMMONLY CONSUMED MEAT PRODUCTS THROUGH RINSING and COOKING by Anna Ellington (Under the Directio
    REDUCTION OF PURINE CONTENT IN COMMONLY CONSUMED MEAT PRODUCTS THROUGH RINSING AND COOKING by Anna Ellington (Under the direction of Yen-Con Hung) Abstract The commonly consumed meat products ground beef, ground turkey, and bacon were analyzed for purine content before and after a rinsing treatment. The rinsing treatment involved rinsing the meat samples using a wrist shaker in 5:1 ratio water: sample for 2 or 5 minutes then draining or centrifuging to remove water. The total purine content of 25% fat ground beef significantly decreased (p<0.05) from 8.58 mg/g protein to a range of 5.17-7.26 mg/g protein after rinsing treatments. After rinsing and cooking an even greater decrease was seen ranging from 4.59-6.32 mg/g protein. The total purine content of 7% fat ground beef significantly decreased from 7.80 mg/g protein to a range of 5.07-5.59 mg/g protein after rinsing treatments. A greater reduction was seen after rinsing and cooking in the range of 4.38-5.52 mg/g protein. Ground turkey samples showed no significant changes after rinsing, but significant decreases were seen after rinsing and cooking. Bacon samples showed significant decreases from 6.06 mg/g protein to 4.72 and 4.49 after 2 and 5 minute rinsing and to 4.53 and 4.68 mg/g protein after 2 and 5 minute rinsing and cooking. Overall, this study showed that rinsing foods in water effectively reduces total purine content and subsequent cooking after rinsing results in an even greater reduction of total purine content.
    [Show full text]
  • Chapter 23 Nucleic Acids
    7-9/99 Neuman Chapter 23 Chapter 23 Nucleic Acids from Organic Chemistry by Robert C. Neuman, Jr. Professor of Chemistry, emeritus University of California, Riverside [email protected] <http://web.chem.ucsb.edu/~neuman/orgchembyneuman/> Chapter Outline of the Book ************************************************************************************** I. Foundations 1. Organic Molecules and Chemical Bonding 2. Alkanes and Cycloalkanes 3. Haloalkanes, Alcohols, Ethers, and Amines 4. Stereochemistry 5. Organic Spectrometry II. Reactions, Mechanisms, Multiple Bonds 6. Organic Reactions *(Not yet Posted) 7. Reactions of Haloalkanes, Alcohols, and Amines. Nucleophilic Substitution 8. Alkenes and Alkynes 9. Formation of Alkenes and Alkynes. Elimination Reactions 10. Alkenes and Alkynes. Addition Reactions 11. Free Radical Addition and Substitution Reactions III. Conjugation, Electronic Effects, Carbonyl Groups 12. Conjugated and Aromatic Molecules 13. Carbonyl Compounds. Ketones, Aldehydes, and Carboxylic Acids 14. Substituent Effects 15. Carbonyl Compounds. Esters, Amides, and Related Molecules IV. Carbonyl and Pericyclic Reactions and Mechanisms 16. Carbonyl Compounds. Addition and Substitution Reactions 17. Oxidation and Reduction Reactions 18. Reactions of Enolate Ions and Enols 19. Cyclization and Pericyclic Reactions *(Not yet Posted) V. Bioorganic Compounds 20. Carbohydrates 21. Lipids 22. Peptides, Proteins, and α−Amino Acids 23. Nucleic Acids **************************************************************************************
    [Show full text]
  • Human Hypoxanthine (Guanine) Phosphoribosyltransferase: An
    Proc. NatL Acad. Sci. USA Vol. 80, pp. 870-873, Febriary 1983 Medical Sciences Human hypoxanthine (guanine) phosphoribosyltransferase: An amino acid substitution in a mutant form of the enzyme isolated from a patient with gout (reverse-phase HPLC/peptide mapping/mutant enzyme) JAMES M. WILSON*t, GEORGE E. TARRt, AND WILLIAM N. KELLEY*t Departments of *Internal Medicine and tBiological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109 Communicated by James B. Wyngaarden, November 3, 1982 ABSTRACT We have investigated the molecular basis for a tration ofenzyme protein. in both erythrocytes (3) and lympho- deficiency ofthe enzyme hypoxanthine (guanine) phosphoribosyl- blasts (4); (ii) a normal Vm., a normal Km for 5-phosphoribosyl- transferase (HPRT; IMP:pyrophosphate-phosphoribosyltransfer- 1-pyrophosphate, and a 5-fold increased Km for hypoxanthine ase, EC 2.4.2.8) in a patient with a severe form of gout. We re-. (unpublished data); (iii) a normal isoelectric point (3, 4) and ported in previous studies the isolation of a unique structural migration during nondenaturing polyacrylamide gel electro- variant of HPRT from this patient's erythrocytes and cultured phoresis (4); and (iv) -an apparently smaller subunit molecular lymphoblasts. This enzyme variant, which is called HPRTOnd0., weight as evidenced by an increased mobility during Na- is characterized by a decreased concentration of HPRT protein DodSO4/polyacrylamide gel electrophoresis (3, 4). in erythrocytes and lymphoblasts, a normal Vm.., a 5-fold in- Our study ofthe tryptic peptides and amino acid composition creased Km for hypoxanthine, a normal isoelectric point, and an of apparently smaller subunit molecular weight. Comparative pep- HPRTLondon revealed a single amino acid substitution (Ser tide mapping-experiments revealed a single abnormal tryptic pep- Leu) at position 109.
    [Show full text]
  • Gout: a Low-Purine Diet Makes a Difference
    Patient HANDOUT Gout: A Low-Purine Diet Makes a Difference Gout occurs when high levels of uric acid in your blood cause crystals to form and build up around a joint. Your body produces uric acid when it breaks down purines. Purines occur naturally in your body, but you also get them from certain foods and drinks. By following a low-purine diet, you can help your body control the production of uric acid and lower your chances of having another gout attack. Purines are found in many healthy foods and drinks. The purpose of a low-purine diet is to lower the amount of purine that you consume each day. Avoid Beer High-Purine Foods Organ meats (e.g., liver, kidneys), bacon, veal, venison Anchovies, sardines, herring, scallops, mackerel Gravy (purines leach out of the meat during cooking so gravy made from drippings has a higher concentration of purines) Limit Moderate- Chicken, beef, pork, duck, crab, lobster, oysters, shrimp : 4-6 oz daily Purine Foods Liquor: Limit alcohol intake. There is evidence that risk of gout attack is directly related to level of alcohol consumption What Other Dietary Changes Can Help? • Choose low-fat or fat-free dairy products. Studies show that low- or non-fat milk and yogurt help reduce the chances of having a gout attack. • Drink plenty of fluids (especially water) which can help remove uric acid from your body. Avoid drinks sweetened with fructose such as soft drinks. • Eat more non-meat proteins such as legumes, nuts, seeds and eggs. • Eat more whole grains and fruits and vegetables and less refined carbohydrates, such as white bread and cakes.
    [Show full text]
  • A Previously Undescribed Pathway for Pyrimidine Catabolism
    A previously undescribed pathway for pyrimidine catabolism Kevin D. Loh*†, Prasad Gyaneshwar*‡, Eirene Markenscoff Papadimitriou*§, Rebecca Fong*, Kwang-Seo Kim*, Rebecca Parales¶, Zhongrui Zhouʈ, William Inwood*, and Sydney Kustu*,** *Department of Plant and Microbial Biology, 111 Koshland Hall, University of California, Berkeley, CA 94720-3102; ¶Section of Microbiology, 1 Shields Avenue, University of California, Davis, CA 95616; and ʈCollege of Chemistry, 8 Lewis Hall, University of California, Berkeley, CA 94720-1460 Contributed by Sydney Kustu, January 19, 2006 The b1012 operon of Escherichia coli K-12, which is composed of tive N sources. Here we present evidence that the b1012 operon seven unidentified ORFs, is one of the most highly expressed codes for proteins that constitute a previously undescribed operons under control of nitrogen regulatory protein C. Examina- pathway for pyrimidine degradation and thereby confirm the tion of strains with lesions in this operon on Biolog Phenotype view of Simaga and Kos (8, 9) that E. coli K-12 does not use either MicroArray (PM3) plates and subsequent growth tests indicated of the known pathways. that they failed to use uridine or uracil as the sole nitrogen source and that the parental strain could use them at room temperature Results but not at 37°C. A strain carrying an ntrB(Con) mutation, which Behavior on Biolog Phenotype MicroArray Plates. We tested our elevates transcription of genes under nitrogen regulatory protein parental strain NCM3722 and strains with mini Tn5 insertions in C control, could also grow on thymidine as the sole nitrogen several genes of the b1012 operon on Biolog (Hayward, CA) source, whereas strains with lesions in the b1012 operon could not.
    [Show full text]
  • Pdfs/0551.Pdf
    1 Structures of the Molecular Components in DNA and RNA with Bond Lengths Interpreted as Sums of Atomic Covalent Radii Raji Heyrovská* Institute of Biophysics of the Academy of Sciences of the Czech Republic, Královopolská 135, 61265 Brno, Czech Republic. *E-mail: [email protected] Abstract: The author has found recently that the lengths of chemical bonds are sums of the covalent and or ionic radii of the relevant atoms constituting the bonds, whether they are completely or partially covalent or ionic. This finding has been tested here for the skeletal bond lengths in the molecular constituents of nucleic acids, adenine, thymine, guanine, cytosine, uracil, ribose, deoxyribose and phosphoric acid. On collecting the existing data and comparing them graphically with the sums of the appropriate covalent radii of C, N, O, H and P, it is found that there is a linear dependence with unit slope and zero intercept. This shows that the bond lengths in the above molecules can be interpreted as sums of the relevant atomic covalent radii. Based on this, the author has presented here (for the first time) the atomic structures of the above molecules and of DNA and RNA nucleotides with Watson-Crick base pairs, which satisfy the known dimensions. INTRODUCTION Following the exciting discovery [1] of the molecular structure of nucleic acids, the question of the skeletal bond lengths in the molecules constituting DNA and RNA has continued to be of interest. The author was enthused to undertake this work by the recent findings [2a, b] that the length of the chemical bond between any two atoms or ions is, in general, the sum of the radii of 2 the atoms and or ions constituting the bond.
    [Show full text]
  • Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
    Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients.
    [Show full text]
  • Xanthine/Hypoxanthine Assay Kit
    Product Manual Xanthine/Hypoxanthine Assay Kit Catalog Number MET-5150 100 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Xanthine and hypoxanthine are naturally occurring purine derivatives. Xanthine is created from guanine by guanine deaminase, from hypoxanthine by xanthine oxidoreductase, and from xanthosine by purine nucleoside phosphorylase. Xanthine is used as a building block for human and animal drug medications, and is an ingredient in pesticides. In vitro, xanthine and related derivatives act as competitive nonselective phosphodiesterase inhibitors, raising intracellular cAMP, activating Protein Kinase A (PKA), inhibiting tumor necrosis factor alpha (TNF-α) as well as and leukotriene synthesis. Furthermore, xanthines can reduce levels of inflammation and act as nonselective adenosine receptor antagonists. Hypoxanthine is sometimes found in nucleic acids such as in the anticodon of tRNA in the form of its nucleoside inosine. Hypoxanthine is a necessary part of certain cell, bacteria, and parasitic cultures as a substrate and source of nitrogen. For example, hypoxanthine is often a necessary component in malaria parasite cultures, since Plasmodium falciparum needs hypoxanthine to make nucleic acids as well as to support energy metabolism. Recently NASA studies with meteorites found on Earth supported the idea that hypoxanthine and related organic molecules can be formed extraterrestrially. Hypoxanthine can form as a spontaneous deamination product of adenine. Because of its similar structure to guanine, the resulting hypoxanthine base can lead to an error in DNA transcription/replication, as it base pairs with cytosine. Hypoxanthine is typically removed from DNA by base excision repair and is initiated by N- methylpurine glycosylase (MPG).
    [Show full text]
  • Purine Metabolism in the Protozoan Parasite Eimeria Tenella (Hypoxanthine-Xanthine-Guanine Phosphoribosyltransferase/GMP-Agarose Affinity Column/Alopurinol) C
    Proc. NatL Acad. Sci. USA Vol. 78, No. 11, pp. 6618-6622, November 1981 Biochemistry Purine metabolism in the protozoan parasite Eimeria tenella (hypoxanthine-xanthine-guanine phosphoribosyltransferase/GMP-agarose affinity column/alopurinol) C. C. WANG AND P. M. SIMASHKEVICH* Merck Institute for Therapeutic Research, Rahway, New Jersey 07065 Communicated by P. Roy Vagelos, June 25, 1981 ABSTRACT Crude extracts of the oocysts ofEimeria tenella, cidia Eimenria tenella, which develops inside the caecal epithe- a protozoan parasite of the coccidium family that develops inside lial cells ofchickens, effectively takes up hypoxanthine and pref- the caecal epithelial cells ofinfected chickens, do not incorporate erentially incorporates label from it into nucleic acids when glycine or formate into purine nucleotides; this suggests lack of grown in cell culture (13, 14). Purine metabolism in this parasite capability for de novo purine synthesis by the parasite. The ex- is particularly interesting in view of the uricotelic metabolism tracts, however, contain high levels of activity of the purine sal- of chickens and the high levels of hypoxanthine known to ac- vage enzymes: hypoxanthine, guanine, xanthine, and adenine cumulate in avian tissues phosphoribosyltransferases and adenosine kinase. The absence of (15). AMP deaminase from the parasite indicates thatE. tenella cannot In this study, we have demonstrated that E. tenella cannot convert AMP to GMP; the latter thus has to be supplied by the perform de novo purine synthesis and examined the detailed hypoxanthine, xanthine, or guanine phosphoribosyltransferase of mechanism of purine salvage. A purine phosphoribosyltrans- the parasite. These three activities are associatedwith one enzyme ferase that uses hypoxanthine and guanine as well as xanthine (HXGPRTase), which has been purified to near homogeneity in as substrates (HXGPRTase) was identified in the parasite.
    [Show full text]
  • Mechanism of Excessive Purine Biosynthesis in Hypoxanthine- Guanine Phosphoribosyltransferase Deficiency
    Mechanism of excessive purine biosynthesis in hypoxanthine- guanine phosphoribosyltransferase deficiency Leif B. Sorensen J Clin Invest. 1970;49(5):968-978. https://doi.org/10.1172/JCI106316. Research Article Certain gouty subjects with excessive de novo purine synthesis are deficient in hypoxanthineguanine phosphoribosyltransferase (HG-PRTase [EC 2.4.2.8]). The mechanism of accelerated uric acid formation in these patients was explored by measuring the incorporation of glycine-14C into various urinary purine bases of normal and enzyme-deficient subjects during treatment with the xanthine oxidase inhibitor, allopurinol. In the presence of normal HG-PRTase activity, allopurinol reduced purine biosynthesis as demonstrated by diminished excretion of total urinary purine or by reduction of glycine-14C incorporation into hypoxanthine, xanthine, and uric acid to less than one-half of control values. A boy with the Lesch-Nyhan syndrome was resistant to this effect of allopurinol while a patient with 12.5% of normal enzyme activity had an equivocal response. Three patients with normal HG-PRTase activity had a mean molar ratio of hypoxanthine to xanthine in the urine of 0.28, whereas two subjects who were deficient in HG-PRTase had reversal of this ratio (1.01 and 1.04). The patterns of 14C-labeling observed in HG-PRTase deficiency reflected the role of hypoxanthine as precursor of xanthine. The data indicate that excessive uric acid in HG-PRTase deficiency is derived from hypoxanthine which is insufficiently reutilized and, as a consequence thereof, catabolized inordinately to uric acid. The data provide evidence for cyclic interconversion of adenine and hypoxanthine derivatives. Cleavage of inosinic acid to hypoxanthine via inosine does […] Find the latest version: https://jci.me/106316/pdf Mechanism of Excessive Purine Biosynthesis in Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency LEIF B.
    [Show full text]